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Abstract
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Previous work established that repeated olanzapine (OLZ) administration in normal adolescent
rats induces a sensitization effect (i.e. increased behavioral responsiveness to drug re-exposure) in
the conditioned avoidance response (CAR) model. However, it is unclear whether the same
phenomenon can be detected in animal models of schizophrenia. The present study explored the
generalizability of OLZ sensitization from healthy animals to a preclinical neuroinflammatory
model of schizophrenia in the CAR. Maternal immune activation (MIA) was induced via
polyinosinic:polycytidilic acid (PolyI:C) administration into pregnant dams. Behavioral
assessments of offspring first identified decreased maternal separation-induced pup ultrasonic
vocalizations and increased amphetamine-induced hyperlocomotion in animals prenatally exposed
to PolyI:C. In addition, repeated adolescent OLZ administration confirmed the generalizability of
the sensitization phenomenon. Using the CAR test, adolescent MIA animals displayed similar
increase in behavioral responsiveness after repeated OLZ exposure during both the repeated drug
test days as well as a subsequent challenge test. Neurobiologically, few studies examining the
relationship between hippocampal cell proliferation and survival and either antipsychotic exposure
or MIA have incorporated concurrent behavioral changes. Thus, the current study also sought to
reveal the correlation between OLZ behavioral sensitization in the CAR and hippocampal cell
proliferation and survival. 5′-bromodeoxyuridine immunohistochemistry identified a positive
correlation between the magnitude of OLZ sensitization (i.e. change in avoidance suppression
induced by OLZ across days) and hippocampal cell proliferation, and a negative correlation
between OLZ sensitization magnitude and hippocampal short term cell survival. The implications
of the relationship between behavioral and neurobiological results are discussed.
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INTRODUCTION

Author Manuscript

The use of antipsychotic drugs (APD) in children and adolescents has increased dramatically
worldwide in recent years (Aparasu and Bhatara, 2007; Kalverdijk et al, 2008; Rani et al,
2008; Wong et al, 2004). APD use for patients under the age of 18 now accounts for about
15% of total usage in the U.S., not only for the management of psychosis, but also for
bipolar disorder, depression, disruptive behavior, and anxiety (Domino and Swartz, 2008).
Clinical studies have established that children and adolescents tend to be more susceptible
than adults to the adverse consequences of APD use, including prolactin elevation and motor
side effects (Haddad and Sharma, 2007; Wudarsky et al, 1999). Preclinical studies in animal
models suggest that this may be due to the differential biological effects APD have on
adolescents versus adults (Choi et al, 2010; Spear et al, 1980). For instance, chronic
treatment of various APD for 21 days significantly reduced the number of dopamine (DA)
D1 receptors in both the medial prefrontal (mPFC) and dorsolateral frontal cortices of
adolescent rats, but not adult rats. In contrast, DA D2 receptor levels were elevated in the
mPFCs of adult rats after chronic APD infusion, but not in adolescent rats (Moran-Gates et
al, 2006).
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Animal studies have also illustrated that application of APD during adolescence, a critical
period for neurodevelopment, can stimulate neuronal and behavioral functional changes that
are reflected in adulthood (Vinish et al, 2013). Adolescent rats chronically exposed to the
atypical APD olanzapine (OLZ) therapy released significantly less DA upon stimulation
during adulthood than vehicle treated rats. Interestingly, our group has also shown that
adolescent APD exposure (postnatal days [P] 35–60, Andersen et al., 2000) can increase
APD response in adulthood, a phenomenon known as “antipsychotic sensitization” (Qiao et
al, 2013a, 2013b, 2014). Although not well understood, APD behavioral sensitization due to
chronic treatment is well documented. For example, the exponential curve of psychotic
symptoms improvement over the first 4 weeks of treatment; the antipsychotic effect growing
with the passage of time (i.e. time-dependent sensitization), and the worsening of
extrapyramidal side effects after years of medication are all well-known demonstrations of
APD sensitization (Agid et al, 2003; Fallon and Dursun, 2011; Kapur et al, 2006).
Clinically, APD sensitization may play an important implication in prescription
considerations, especially after drug abstinence. Furthermore, concerning the adolescent
patient population, APD sensitization may interact with developmental trajectories to alter
adulthood behavior and brain functions.
In a previous study, we showed that OLZ, an APD widely prescribed in the adolescent
population, induces an increased behavioral sensitivity over repeated treatment during
adolescence (Pakyurek et al, 2013). This increase in sensitivity remains evident when rats
are re-exposed to OLZ in adulthood (Qiao et al, 2013a). The study employed the rat
Brain Res. Author manuscript; available in PMC 2016 August 27.
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conditioned avoidance response (CAR) test to measure APD response. This test is widely
used and well-validated for assessing APD activity in rodents, and numerous studies have
verified that clinically relevant doses of APD suppress avoidance behavior in animals
(Wadenberg and Hicks, 1999; Wadenberg, 2010; Wadenberg et al, 1997). The model is
commonly used to predict the clinical potency of APD, and thus an ideal measure of
behavioral sensitization over repeated exposure (Arnt, 1982; Wadenberg et al, 2001).

Author Manuscript

One mechanism that may be associated with long term APD sensitization is drug-induced
changes in cell proliferation and survival. While the effects of APD on cell growth are still
inconsistent across studies, long-term administration of APD has been reported by some to
increase cell proliferation in the subventricular zone as well as the subgranular zone of the
hippocampus in adult animals (Halim et al, 2004; Keilhoff et al, 2010; Maeda et al, 2007;
Wakade et al, 2002; Wang et al, 2004). However, no prior study has considered this effect
of APD as a potential mechanism of APD sensitization in adolescence. Also, much of our
APD sensitization work has used otherwise healthy rats, and it remains to be elucidated
whether APD sensitization is generalizable and can also be demonstrated in preclinical
disease models. In the present study, we addressed this issue by testing OLZ in a rat
maternal immune activation (MIA) model of schizophrenia, a well-studied model that
gained much popularity in the recent decade (Meyer and Feldon, 2010). Adult rodent
offspring born to infected mothers displayed specific histological and behavioral
abnormalities relevant to those seen in human patients with schizophrenia, including
increased prefrontal cortical pyramidal cell density (Fatemi et al, 1999), deficits in learning
(Shi et al, 2003), sensorimotor gating (Wolff and Bilkey, 2008), latent inhibition
(Zuckerman and Weiner, 2003), and working memory (Ozawa et al, 2006).
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Examination of hippocampal cellular changes associated with OLZ sensitization using a
preclinical model is relevant to the treatment of schizophrenia. First, impaired hippocampal
cell proliferation is thought to contribute to cognitive deficits in schizophrenia, and
induction of hippocampal cell growth has been suggested as a possible therapeutic
mechanism of APD treatment (Kempermann et al, 2008; Reif et al, 2006, 2007; Toro and
Deakin, 2007). However, it is unclear whether the induction of cell proliferation by
antipsychotics is related to behavioral phenotypes that are representative of drug efficacy.
Secondly, MIA as a preclinical model of schizophrenia has been shown to reduce
neurogenesis in some studies, and one previous study suggested that APD treatment may
reverse this dysfunction (Cui et al, 2009; Piontkewitz et al, 2012b; Vuillermot et al, 2010;
Wolf et al, 2011). However, no study has connected this cellular change in MIA animals
with behavioral effects, which warrants the current idea of examining the relationship
between cell proliferation and survival associated with APD treatment and the CAR
behavior observed in a preclinical model.
In this study, we investigated the potential connection between the induction and expression
of OLZ sensitization in adolescent rats and OLZ-induced cell proliferation and survival in
the dentate gyrus (DG) of rat hippocampi, using the CAR task for behavioral assessment and
5′-bromodeoxyuridine (BrdU) immunohistochemistry for cellular examination, respectively.
In addition, various behavioral assays were used to assess MIA-induced behavioral
impairments. These included maternal separation-induced 40 kHz pup ultrasonic
Brain Res. Author manuscript; available in PMC 2016 August 27.
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vocalizations (USV) on P11, an assay for early communicative behavior and stress response
(Ming et al, 2011); prepulse inhibition (PPI) in adolescence (P43), an assay for sensorimotor
gating ability (Geyer and Braff, 1987; Swerdlow et al, 2008); and amphetamine-induced
hyperlocomotion in adulthood (P84), an assay for both DAergic defect as well as APD
efficacy (Arnt, 1995; Laruelle et al, 1996, 1999). In assessing ultrasonic vocalizations, we
expect MIA animals to exhibit decreased total number of vocalizations after maternal
separation, as previous studies have indicated communication deficits in MIA offspring
using a similar paradigm (Malkova et al, 2012). While PPI results have been somewhat
inconclusive regarding MIA offspring assessments due to variations in experimental
procedure, we hypothesize a deficit in sensory-motor gating based on previous report using
parameters similar to the current study (Wolff and Bilkey, 2010). Finally, Zuckerman et al,
2003 previously reported an increase in amphetamine-induced hyperlocomotion in adult
MIA offspring, and we hypothesize a similar finding in the current study.

Author Manuscript

Thus, the overall goals of the study were twofold. First, we sought to identify whether OLZ,
an APD widely prescribed in the adolescent population, produces behavioral sensitization in
adolescent MIA animals. This confirms whether the adolescent OLZ sensitization
phenomenon in healthy animals can generalize into a preclinical animal model of psychiatric
disorders. Secondly, we also sought to investigate whether changes in cell proliferation and
survival in the DG of the hippocampus are associated with the CAR sensitization induced by
repeated OLZ exposure. We hypothesized that OLZ sensitization is a generalizable
phenomenon that can be observed in MIA animals, and that the CAR sensitization induced
by repeated OLZ exposure is associated with changes in cell proliferation and survival
within the DG of the hippocampus.

Author Manuscript

RESULTS
Experiment 1: Assessment of MIA behavioral alterations during early postnatal period and
adulthood
We first established the validity of our MIA model by assessing phenotypic alterations at
three time points: one day post PolyI:C treatment, early postnatal period, and adulthood.
During gestation, we measured the percentage of pregnant dam weight change one day
following saline or PolyI:C injection (Fig. 1a). One way ANOVA revealed a main effect of
prenatal treatment, F(1,66)=10.910, p=0.002. This suggest that treatment of PolyI:C during
gestation transiently decreased the amount of weight gain in pregnant females,
demonstrating the effectiveness of PolyI:C.

Author Manuscript

Next, we further examined schizophrenia related phenotypes in MIA animals during the
early postnatal period. Pup USV serve as an important communication tool from pups to
mothers, and MIA is reported to cause an alteration in this behavior (Malkova et al, 2012).
Here we assessed the number of maternal separation-induced USV made by pups on P11
(Fig. 1b). Repeated measures two-way ANOVA revealed a main effect of call type,
F(3,94)=53.75, p<0.001, and a call type × prenatal treatment interaction, F(3,94)=3.221,
p=0.026. One way ANOVA on the individual call types revealed a main effect of prenatal
treatment for long calls, F(1,98)=9.491, p=0.003 and total number of calls, F(1,98)=4.011,
p=0.048. These findings strengthen the hypothesis that prenatal exposure to MIA may
Brain Res. Author manuscript; available in PMC 2016 August 27.
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impair pup social communications, and provide extended information on specific call type
alterations.
Finally, as sensitivity to amphetamine is shown to be elevated in adult MIA offspring
(Piontkewitz et al., 2011), we examined differences between prenatal treatment conditions in
amphetamine-induced hyperlocomotion during adulthood. Figure 1c shows the mean
locomotor activities as measured by the number of photobeam breaks throughout the 60-min
test period after the amphetamine injections. Repeated measures two-way ANOVA revealed
a main effect of time blocks, F(11,30)=14.001, p<0.001, and a marginal effect of prenatal
treatment, F(1,40)=3.925, p=0.054. These findings suggest that prenatal exposure to MIA
increased sensitivity to amphetamine in adult offspring, mimicking increased vulnerability
to psychotomimetic drugs.

Author Manuscript

Experiment 2: Evaluation of OLZ sensitization in the conditioned avoidance response test
and hippocampal cell proliferation and survival in MIA and saline rats
Using the validated MIA model, we next examined OLZ sensitization using the CAR test.
The procedure consisted of four phases: avoidance training, post training PPI assessment,
induction of OLZ sensitization, and expression of OLZ sensitization.
The first phase of CAR testing is the avoidance training. Repeated measures two-way
ANOVA of percentage avoidance responses throughout the 10 CAR training days revealed
only a main effect of day, F(9,82)=25.224, p<0.001, but no main effect of prenatal treatment
(Fig. 2a). While performance from the first two days of CAR training suggests possible
differences, the effect is not significant.

Author Manuscript

Following 10 days of avoidance training, all animals were assessed for PPI to examine
differences in sensorimotor gating functions. Figure 2b and 2c shows the percentage of PPI
and the magnitude of ASR one day following CAR training (P 43), respectively. There was
no main effect of prenatal treatment on PPI, nor a prenatal treatment × prepulse level
interaction. There was also no significant difference between the ASR of the two conditions.

Author Manuscript

Next, animals underwent five days of OLZ administration for induction of drug
sensitization. Figure 3a and b shows the percentage of avoidance responses throughout the
five test days. During this sensitization induction phase, OLZ treatment consistently
disrupted avoidance response. Repeated measures two-way ANOVA analysis on the overall
avoidance data for each drug treatment condition revealed a main effect of day,
F(4,83)=25.301, p<0.001, drug groups, F(2,86)=426.523, p<0.001, and a significant day ×
drug group interaction, F(8,168)=3.111, p=0.003 (Fig. 3b). Post hoc LSD tests revealed that
the 3 drug groups all differed significantly from each other, all p<0.001. There was no
significant difference between prenatal treatments (Fig. 3a).
Prior to challenging the animals with low dose OLZ to assess sensitization expression, all
animals underwent two days of drug free retraining sessions, the first with only the
conditioned stimulus of noise present, and the second session with both the conditioned
stimulus of noise and the unconditioned stimulus of shock. This ensured that all animals
return to a high baseline of CAR behavior before the OLZ challenge. Figure 3c and d shows

Brain Res. Author manuscript; available in PMC 2016 August 27.
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the percentage of avoidance responses on the two retraining days and the OLZ sensitization
challenge day. There was no group difference on the retraining days between prenatal
treatment and drug groups, although repeated measures two-way ANOVA of the retraining
days did reveal a main effect of day, F(1,86)=30.747, p<0.001.
Finally, after two days of drug free sessions, animals were challenged with OLZ 0.5 mg/kg
to assess the expression of OLZ sensitization. Multifactorial ANOVA revealed a significant
effect of drug group, F(2,86)=26.749, p<0.001 (Fig. 3). Post hoc LSD tests showed that the
OLZ 1.0 and 2.0 mg/kg groups were significantly lower in percent avoidance than the VEH
group, p<0.001 for both, confirming the OLZ sensitization effect. The two OLZ groups did
not differ significantly from each other. There was also no significant difference between
prenatal treatments (Fig. 3d). These results suggest that the OLZ sensitization is a general
behavioral pharmacological phenomenon irrespective of prenatal treatment conditions.

Author Manuscript

To assess the relationship between OLZ sensitization and hippocampal cell proliferation and
survival, all animals were sacrificed after the OLZ challenge, and 5′-bromodeoxyuridine
(BrdU) immunoreactivity was measured. Figure 4a depicts a sample micrograph of BrdU
labeling in the subgranular zone of the hippocampal dentate gyrus.

Author Manuscript
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Cell proliferation was assessed in animals injected with BrdU during the drug free retraining
days, while survival was assessed in animals injected with BrdU immediately prior to the
repeated drug test days. Separate repeated two-way ANOVAs found no significant
difference in the number of BrdU+ cells between prenatal or drug treatment groups in both
cell proliferation (Fig. 4b) or short term cell survival (Fig. 4c). Interestingly, however, there
was a differential association between OLZ sensitization and cell proliferation between the
MIA and SAL offspring. While the magnitude of OLZ sensitization from day one to two of
drug administration had no correlation with the number of BrdU+ cells assessed for
proliferation (Fig. 4d, Person’s r=−0.005, p=0.983) in SAL animals, the highest percent
avoidance suppression from day one to two of drug administration corresponded to the
highest number of BrdU+ cells (Fig. 4e, Pearson’s r=0.527, p=0.030) in MIA animals
injected with BrdU 48 hours prior to sacrifice. On the contrary, correlational analysis further
revealed a different pattern of association between the magnitude of OLZ sensitization and
short term cell survival between MIA and SAL animals. While the magnitude of OLZ
sensitization from day one of drug administration to the challenge assessment had no
correlation with the number of BrdU+ cells assessed for survival (Fig. 4f, Person’s r=0.162,
p=0.533) in MIA animals, the highest percent of avoidance suppression from day one of
drug administration to the challenge assessment corresponded to the lowest number of BrdU
+ cells in SAL animals injected with BrdU 9 days prior to sacrifice (Fig. 4g; Pearson’s r=
−0.910, p<0.001). These results suggest that the magnitude of OLZ sensitization, as assessed
by the extent of the CAR disruption over days, is associated with the increase in acute cell
proliferation rate for MIA animals and the decrease in short term cell survival rate for SAL
animals.
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DISCUSSION
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The present study investigated the association between hippocampal cell growth and
survival and adolescent OLZ sensitization in the CAR test using the MIA model of SZ. We
found decreased pup USV and increased amphetamine sensitivity in MIA animals,
validating that MIA animals do in fact display altered behaviors in preclinical assays
relevant to SZ (Malkova et al, 2012; Piontkewitz et al, 2011). Using a two-phase paradigm
we developed, we showed that repeated OLZ exposure sensitized MIA animals not only
throughout the repeated drug test days, but also in the subsequent challenge test, with rats
previously treated with OLZ having a stronger response to OLZ than drug naïve animals. So
far, few groups have studied the effects of APD in MIA (Arad and Weiner, 2012;
Piontkewitz et al, 2009, 2011, 2012b). Here we established that adolescent OLZ behavioral
sensitization is a stable phenomenon irrespective of disease state. Furthermore, the present
study extended our work on the neurobiological basis of OLZ sensitization by investigating
hippocampal cellular changes (Zhao and Li, 2010; Zhao et al, 2012). The results indicated
that cell proliferation correlated positively with the magnitude of OLZ induced CAR
sensitization in MIA animals, while cell survival correlated negatively with sensitization
magnitude in SAL animals.
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MIA is a widely accepted disease model of SZ (Meyer and Feldon, 2010; Patterson, 2009).
Epidemiological surveys in the human population indicate that bacterial and viral infections
during the second trimester increase the risk of neurodevelopmental psychiatric disorders in
the offspring by two fold (Boksa, 2008; Brown, 2006; Brown et al, 2000). These infections
may activate the mother’s immune system, increasing cytokine expressions, disrupting
offspring neurodevelopment, and causing SZ related phenotypes (Meyer and Feldon, 2009;
Smith et al, 2007). Preclinical studies show that in utero exposure to immunostimulants such
as lipopolysaccharide (LPS) and PolyI:C disrupts SZ relevant behaviors, including latent
inhibition ([LI]; Meyer et al, 2010; Zuckerman and Weiner, 2003; Zuckerman et al, 2003),
amphetamine-induced hyperlocomotion (Vorhees et al, 2012; Zager et al, 2012), and
sensory-motor gating (Basta-Kaim et al, 2012; Wolff and Bilkey, 2008). Here we showed
that rat pups prenatally exposed to PolyI:C exhibited abnormal USV patterns on P11 after 20
minutes of maternal separation. So far there have been few studies that assessed this social
communication deficit (Malkova et al, 2012; Yee et al, 2012), and our results complement
current knowledge with detailed analyses of the call types, namely the long, short, and
frequency modulating calls in the 40kHz range of pup vocalizations (Brudzynski et al, 1999;
Ming et al, 2011). While PolyI:C offspring made fewer calls overall, the number of long
calls were especially decreased in MIA offspring compared to control animals. In addition,
our findings of increased amphetamine-induced hyperlocomotion in adult MIA animals are
consistent with others (Meyer et al, 2010; Vorhees et al, 2012; Zager et al, 2012;
Zuckerman et al, 2003). On instrumental learning and pre-attentive processing, we found no
differences between adolescent control and MIA animals in either CAR acquisition or PPI,
though the first and second days of avoidance training suggested a lower performance in the
MIA group. Various reviews have alluded to differences in MIA procedures and age of
assessment as sources of discrepancies (Fortier et al, 2007; Meyer and Feldon, 2012). For
example, Basta-Kaim et al, 2012 saw PPI deficits in offspring exposed to LPS only on P90,
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but not P30, while Wolff and Bilkey, 2010 observed PPI deficits on P35 in offspring
exposed to PolyI:C. In learning, Zuckerman et al, 2003 found LI disruption in 3 month-old
offspring, but not P35. Meyer et al, 2006 further confirmed that behavioral inconsistencies
may be attributed to MIA timing, as offspring from dams treated with PolyI:C on G6, 9, and
13 exhibited LI deficits, but not those on G17. These discrepancies suggest that while MIA
is a valid preclinical model, different manipulations can produce variable results.
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In this study, we demonstrated behavioral sensitization to repeated OLZ exposure in MIA
offspring using the CAR assay, as we have previously shown in normal animals (Mead and
Li, 2010; Qiao et al, 2013a; Sparkman and Li, 2012; Swalve and Li, 2012; Zhang and Li,
2012). As most patients on APD receive chronic treatments (Kalverdijk et al, 2008), and in
recent years there has been a decrease in the age of treatment onset (Aparasu and Bhatara,
2007; Olfson et al, 2006; Rani et al, 2008; Wong et al, 2004), preclinical studies addressing
adolescent chronic APD use are critical for translational values. We have shown previously
that repeated APD exposure alters the behavioral sensitivity of animals to subsequent
treatments (Gao and Li, 2013; Mead and Li, 2010; Qiao et al, 2013a; Qin et al, 2013;
Swalve and Li, 2012), and that this phenomenon is persistent from adolescence to adulthood
(Qiao et al, 2013a, 2013b). Here we further determined that OLZ sensitization is
independent of the disease state of the animal, suggesting that long term neural changes can
occur rapidly with repeated APD exposure in this population also.
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Using a pharmacological approach, we previously identified that dopamine D2 and serotonin
(5HT) 2a receptors are involved in APD sensitization (Li et al, 2010, 2012; Qiao et al,
2014). The current study targeted hippocampal cell growth as a potential contributor. While
APD are largely developed according to DA and 5HT receptor antagonism, changes in cell
growth and survival may be of significance in enhancing therapeutic efficacy. Current
literature regarding this issue remains inconsistent, perhaps due to discrepancies in
paradigms, dosages, and assessment time points (Keilhoff et al, 2012). For example, Halim
et al, 2004 found that 28 days of clozapine (CLZ) increased dentate gyrus (DG) cell
proliferation in healthy animals, but not survival. In contrast, Maeda et al, 2007 showed that
while 14 days of CLZ protected against PCP-impaired cell proliferation, CLZ alone
produced no change. Here we identified correlations between cellular measures and OLZ
sensitization. Namely, that sensitization is positively correlated with cell proliferation for
MIA animals and negatively correlated with survival for SAL animals.
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In the present work, the number of BrdU-labeled cells that survived for nine days in SAL
animals correlated negatively with the magnitude of OLZ sensitization. Here, a larger
decrease in avoidances over days corresponded with a smaller number of newborn cells that
survived, suggesting that individual OLZ sensitivity is associated with drug-related changes
in cell survival. In addition, the number of BrdU-labeled cells two days post injections
correlated positively with the magnitude of avoidance suppression (i.e. OLZ sensitization in
CAR) in MIA animals. Thus, a larger decrease in avoidances over days corresponded with a
larger number of newborn cells, suggesting that individual OLZ sensitivity in MIA is
associated with drug-related changes in cell growth. The increase in MIA cell proliferation
echoes previous findings(Halim et al, 2004; Kodama et al, 2004). For example, Kodama et
al, 2004 showed that 21 days of OLZ treatment in healthy subjects was able to increase cell
Brain Res. Author manuscript; available in PMC 2016 August 27.

Chou et al.

Page 9

Author Manuscript

proliferation in the DG. Here, our concurrent examination of hippocampal cellular changes
and behavioral responsiveness suggests that differential sensitivity to OLZ is associated with
individual variability in cell growth and pruning. As patient evaluation studies such as
Stroup, 2007 indicate that patients with schizophrenia exhibit diverse reactions to APD
treatment, our observation highlights the role of cell proliferation and survival as a marker of
individual sensitivity to APD.
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So far only Piontkewitz et al, 2012b have explored the effects of APD on MIA hippocampal
changes. While the group reported increased cell survival in MIA, the study assessed
survival of cells born post-APD treatment and at three weeks post BrdU injection, thus
differing from our cell survival throughout the drug treatment period. Our result of a positive
correlation between the magnitude of OLZ behavioral sensitization and MIA hippocampal
cell proliferation suggests possible differences in adolescent brain response to repeated OLZ
exposure between disease and healthy animals despite similar behavioral outputs. Indeed,
while Piontkewitz et al, 2012b did not examine cell proliferation, the authors found that
risperidone differentially affected 21-day cell survival between adolescent MIA and control
animals. The underlying mechanism of how APD treatment alters MIA cell proliferation and
survival is unknown, and our findings suggest the increase in hippocampal cell proliferation
as a possibility.
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Various studies have considered the effects of APD on cell survival under different
durations – 14, 21, or 28 days. The duration of nine days was fitting for this study as it
covered only the CAR assessment and drug treatment period. This prevented potential
environmental confounds post OLZ treatment and CAR testing. While no parametric study
exists regarding the progression of hippocampal cell survival over time under the influence
of APD, it is likely that APD related changes in cell survival vary over time.
One limitation of this study is the uncertainty of the phenotypes of BrdU+ cells. While the
focus here was not to determine hippocampal cell proliferation and survival specific to the
neuronal lineage, it is important to remember that hippocampal stem cells not only give rise
to neurons, but various supporting cell types including oligodendrocytes and endothelial
cells (Kodama et al, 2004; Wang et al, 2004). Some above-mentioned studies investigating
APD and hippocampal alterations have found that most BrdU+ cells are also NeuN+.
However, studies have also suggested that disease mechanisms of SZ may involve deficits in
non-neuronal cells (Benes and Berretta, 2001; Zhang and Reynolds, 2002), lending the
notion that proliferation of all cell types may contribute to APD therapeutic efficacy.
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In summary, results from the current study provided clinically relevant information. First,
we verified that OLZ behavioral sensitization occurs in a disease model of SZ, confirming
that this phenomenon is irrespective of disease state and offers a reference in creating
therapeutic regimen. Secondly, the association between the magnitude of behavioral
sensitization and hippocampal cell proliferation and survival provides novel additional
insight regarding mechanisms associated with APD sensitization. Further investigation into
whether hippocampal cell proliferation and pruning are necessary and sufficient to induce
APD sensitization and generate increased therapeutic efficacy may lead to superior
pharmacological management.
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METHODS
Animals
Sixty-eight pregnant Sprague-Dawley dams from Charles River (Portage, MI; gestation day
[G] 6 on delivery date) and their offspring were used. Pregnant dams were single housed in
48.3 × 26.7 × 20.3 cm transparent polycarbonate cages under 12h light/dark conditions (light
on between 0630 and 1830 h). Rat pups remained with dams until weaning (P21), upon
which they were separated and housed two per cage in 182 × 50 × 188.1 cm transparent
polysulfone individually ventilated cages. Room temperature was maintained at 22 ± 1°C
with a relative humidity of 45–60%. Food and water was available ad libitum. All
experiments were run during the light cycle. All procedures were approved by the
Institutional Animal Care and Use Committee at the University of Nebraska-Lincoln.
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Drugs and choice of doses
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Polyinosinic:polycytidylic acid (PolyI:C, 4.0 mg/kg, intravenous [iv]; Sigma Aldrich, St.
Louis, MO) was dissolved in 0.9% saline. This dose of PolyI:C was chosen based on
previous studies using the same dose and route of administration to generate schizophrenialike phenotypes (Piontkewitz et al, 2009, 2012a, 2012b; Wolff and Bilkey, 2008, 2010; Yee
et al, 2012; Zuckerman and Weiner, 2005; Zuckerman et al, 2003). Olanzapine (OLZ) 0.5,
1.0, and 2.0 mg/kg (subcutaneous [sc]; gifts from the NIMH drug supply program) were
dissolved in distilled sterile water with 1.0–1.5% glacial acetic acid. The 1.0 and 2.0 mg/kg
OLZ acutely inhibit CAR without inducing catalepsy based on our previous work (Feng et
al, 2013; Li et al, 2004, 2007, 2009; Mead and Li, 2010; Qiao et al, 2013a, 2013b; Sun et al,
2009; Zhang and Li, 2012; Zhao and Li, 2010). The lower challenge dose of 0.5 mg/kg OLZ
has been successfully used in our previous studies (Mead and Li, 2010; Qiao et al, 2013a;
Sparkman and Li, 2012; Swalve and Li, 2012; Zhang and Li, 2012) and prevents the floor
effect (i.e. a high dose may cause maximal avoidance disruption and obscures the
sensitization effect). The injection solution of amphetamine (1.5mg/kg, sc; Sigma Aldrich,
St. Louis, MO) was obtained by mixing the drug with 0.9% saline. The dosage was chosen
based on previous work showing robust hyperlocomotion without severe stereotypy (Sun et
al, 2009). PolyI:C, OLZ and amphetamine were all administered at 1.0 ml/kg. 5′bromodeoxyuridine (BrdU, 75 mg/kg, ip; Sigma Aldrich, St. Louis, MO) was dissolved in
0.9% saline (10 mg/ml) and administered at 7.5 ml/kg. This dosage and administration
protocol of BrdU was chosen based on previous studies indicating clear labeling of dividing
cells (Halim et al, 2004; Maeda et al, 2007; Wang et al, 2004).
Prenatal treatment

Author Manuscript

Prenatal PolyI:C treatment was performed on G15, when pregnant dams were anesthetized
with 3% isoflurane (Fisher Scientific, Denver, CO) in 98% O2 and given a single iv
injection at the tail vein. Weight changes of pregnant dams were measured and recorded one
day post PolyI:C administration. For control comparison, half of the G15 pregnant dams
were injected with saline at the tail vein, creating offspring that served as control animals
without prenatal immune activation.
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Two-way avoidance conditioning apparatus
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Eight identical two-way shuttle boxes (Med Associates, St. Albans, VT) were used. Each
box (64 cm W × 24 cm D × 30 cm H from grid floor) was housed in a ventilated, soundinsulated isolation cubicle (96.52 cm W × 35.56 cm D × 63.5 cm H). Each box was divided
into two equal-sized compartments by a partition with an arch style doorway (15 cm H × 9
cm D at base) and a barrier (4 cm H from grid floor) so that rats had to jump in order to
cross from one compartment to the other. The grid floor consisted of 40 stainless-steel rods
measuring 0.48 cm in diameter spaced 1.6 cm apart center to center, through which a
scrambled footshock (unconditioned stimulus [US], 0.8mA, maximum duration: 5 s) was
delivered by a constant current shock generator (Model ENV-410B) and scrambler (Model
ENV-412). The rat location and crossings between compartments were monitored by a set of
16 photobeams (ENV-256-8P) affixed at the bottom of the box (3.5 cm above the grid
floor). Illumination was provided by two houselights mounted at the top of each
compartment. The conditioned stimulus (CS; i.e. 76 dB white noise) was produced by a
speaker (ENV 224 AMX) mounted on the ceiling of the cubicle, centered above the shuttle
box. Background noise (~74 dB) was provided by a ventilation fan affixed at the top corner
of each isolation cubicle. All training and testing procedures were controlled by Med
Associates programs running on a computer.
Pup ultrasonic vocalization (USV) recording apparatus

Author Manuscript

In each CAR box, an USV microphone (P 48/Emkay Microphone, Avisoft Bioacoustics,
Berlin, Germany) was mounted on the ceiling of the two-compartment chamber. The
microphone was connected via an E-MU 0404 USB Audio device to a computer. Acoustic
data were displayed in real time by the Avisoft RECORDER, a multi-channel triggering
hard-disk recording software (version 3.4; Avisoft Bioacoustics), and were recorded at a
sampling rate of 192 kHz in 16 bit format. For acoustical analysis, recordings were
transferred to Avisoft SASLab Pro (Version 4.51) and a fast Fourier transformation (FFT)
was conducted. Spectrograms were generated with an FFT-length of 256 points and a time
window overlap of 50% (100% Frame, FlatTop window). The spectrogram was produced at
a frequency resolution of 750 Hz and a time resolution of 0.6667 ms. Call detection was
provided by an automatic single threshold-based algorithm (threshold: −20 dB) and a holdtime mechanism (hold time: 0.02 s).
Prepulse inhibition (PPI) of acoustic startle response (ASR) apparatus

Author Manuscript

The PPI test was performed using six Startle Monitor Systems (Kinder Scientific, Julian,
CA). Each system, controlled by a PC, was housed in a compact sound attenuation cabinet
(36 cm wide × 28 cm deep × 50 cm high). A speaker (diameter: 11 cm) mounted on the
cabinet’s ceiling was used to generate acoustic stimuli (70 dB-120 dB). The startle response
was measured by a piezoelectric sensing platform on the floor, which was calibrated daily.
During testing, rats were placed in a rectangular box made of transparent Plexiglas (19 cm
wide × 9.8 cm deep × 14.6 high) with an adjustable ceiling positioned atop the box,
providing only limited restraint while prohibiting ambulation.
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Locomotor activity monitoring apparatus
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Sixteen 48.3 cm × 26.7 cm × 20.3 cm transparent polycarbonate activity boxes were housed
in a quiet room. Each was equipped with a row of 6 photocell beams (7.8 cm between two
adjacent photobeams) placed 3.2 cm above the floor of the cage. A computer with recording
software (Aero Apparatus Sixbeam Locomotor System v1.4) was used to detect the
disruption of the photocell beams and recorded the number of beam breaks.
Experiment 1: Assessment of MIA behavioral alterations during early postnatal period and
adulthood

Author Manuscript

To establish the validity of our MIA model, we examined offspring behavior in two
behavioral assays that have previously been reported to show abnormal phenotypes by MIA:
pup USV (Malkova et al, 2012) and adult amphetamine-induced hyperlocomotion
(Piontkewitz et al, 2011).

Author Manuscript

Pup USV induced by maternal separation—Pup USVs serve as an important social
communication tool from pups to mothers. MIA is reported to cause an alteration in this
behavior (Malkova et al, 2012). This experiment was designed to validate this behavioral
abnormality associated with MIA. The procedure was similar to that previously used in our
lab (Ming et al, 2011). Experimentally naïve rats (1 male and 1 female pup; SAL, n=50;
MIA, n=50) from each litter was used on P11 for the experiment. Pups were separated from
their dams and placed in plastics bowls (one pup per bowl, 14.5 and 9.0 cm wide at the top
and bottom, 7.5 cm high) on heating pads (~35°C). Twenty minutes later, the bowls and
pups were placed in the CAR chambers directly underneath the microphone. USV were
recorded for 3 minutes. For acoustical analysis, recordings were transferred to Avisoft
SASLab Pro (Version 4.51) and a fast Fourier transformation (FFT) was conducted.
Spectrograms were generated with an FFT-length of 256 points and a time window overlap
of 50% (100% Frame, FlatTop window). The spectrogram was produced at a frequency
resolution of 750 Hz and a time resolution of 0.6667 ms. Call detection was provided by an
automatic dual threshold-based algorithm and a hold-time mechanism (hold time: 0.02 s).
The primary threshold was defined at −40 dB, while the start/end threshold was defined at
−20 dB. Pup USV were classified into three types by a custom-built computer program.
“Long” USV were defined as waveforms that were greater than 50 ms long, with a
frequency deviation of less than 3 kHz. “Short” USV weny waveforms that were less than
50 ms long. “Frequency-modulated” USV were greater than 50 ms long and had a frequency
deviation of greater than 3 kHz. A comparison between this automatic quantification method
and human scoring on four randomly selected tests revealed a high degree of agreement,
with a Pearson’s product moment correlation ranging from 0.979 to 0.998.

Author Manuscript

Adult amphetamine-induced hyperlocomotion—Sensitivity to amphetamine is
elevated in adult MIA offspring as a measure of hyperDAergic function (Piontkewitz et al.,
2011). This experiment examined possible differences between prenatal treatment
conditions in amphetamine-induced hyperlocomotion during adulthood. Separate groups of
male and female adult offspring that were not used in OLZ testing were tested on P84,
which also include some rats tested for pup USVs. The procedure was similar to that
previously used in our lab (Sun et al, 2009). Rats were first habituated to the locomotor
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activity apparatus for 30 min. They were then taken out of the activity monitoring boxes,
injected with 0.9% saline and replaced immediately back into the boxes. At the end of
another 30 min period, rats were taken out and injected with amphetamine and placed back
in the boxes for another 60 min. Locomotor activity (number of photobeam breaks) was
measured and recorded in 5 min intervals throughout the entire 120 min testing session.
Experiment 2: Evaluation of OLZ sensitization and hippocampal cell proliferation and
survival in the conditioned avoidance response test using MIA and control animals

Author Manuscript

This experiment examined whether OLZ sensitization was differentially expressed in the
MIA and saline male rats and whether cell proliferation in the dentate gyrus (DG) was
altered by OLZ exposure to mediate OLZ sensitization in the CAR test. No more than 2
male pups from each litter were used in this experiment in order to minimize litter effects
(Zorrilla, 1997). The overall experimental procedure was similar to that previously reported
(Mead and Li, 2010; Qiao et al, 2013a; Swalve and Li, 2012) and consisted of four phases:
avoidance training, post training PPI assessment, induction of OLZ sensitization, OLZ
sensitization assessment, and cell proliferation and survival assay by BrdU
immuohistochemistry

Author Manuscript

Avoidance training—Adolescent Sprague-Dawley males (P31) were first habituated to
the CAR boxes for 2 days (30min/day) and then trained for conditioned avoidance
responding for 10 consecutive days/sessions. Each session consisted of 30 trials. Every trial
started by presenting a white noise (CS) for 10s, followed by a continuous scrambled foot
shock (0.8 mA, US, maximum duration = 5 s) on the grid floor. An avoidance response was
recorded if the subject crosses into the adjacent compartment within the duration of the CS
presentation. An escape response was recorded if the subject crosses into the adjacent
compartment during the US presentation. If the rat made no response throughout both CS
and US, the trial was terminated and recorded as an escape failure. The total number of
avoidance responses was recorded for each session. Inter-trial intervals varied randomly
between 30 and 60s.

Author Manuscript

PPI of ASR assessment—One day after the CAR training (P43), rats were tested for a
single session of PPI in order to examine possible differences between prenatal treatment
conditions. Rats were placed in the PPI boxes and tested according to procedures adapted
from Culm and Hammer, 2004. The PPI session lasted approximately 18 min and began
with a 5 min period of 70 dB background noise that continued throughout the duration of the
session. The 5 min background was followed by four different trial types: PULSE ALONE
trials and three types of PREPULSE+PULSE trials, which consisted of a 20 ms 73, 76, or 82
dB prepulse (3, 6, and 12 dB above background) followed 100 ms later by a 120 dB pulse.
The session was divided into 4 blocks. Blocks 1 and 4 were identical, each consisting of 4
PULSE ALONE trials. Blocks 2 and 3 were also identical and each consisted of 8 PULSE
ALONE trials and 5 of each PREPULSE+PULSE trial type. A total of 54 trials were
presented. Trials within each block were presented in a pseudorandom order and were
separated by a variable intertrial interval averaging 15 s (ranging from 9 to 21 s). Startle
magnitude of the acoustic startle response (ASR) was defined as the maximum force
(measured in Newtons) applied by the rat to the startle apparatus recorded over a period of

Brain Res. Author manuscript; available in PMC 2016 August 27.

Chou et al.

Page 14

Author Manuscript

100 ms beginning at the onset of the pulse stimulus. Between each stimulus trial, 100 ms of
activity was recorded when no stimulus was present. These trials were called NOSTIM trials
and were not included in the calculation of intertrial intervals. Responses recorded during
NOSTIM trials are considered a measure of gross motor activity within the PPI boxes.
Startle responses from testing blocks 2 and 3 were used to calculate percent prepulse
inhibition (%PPI) for each acoustic prepulse trial type:

Author Manuscript

Repeated OLZ testing in CAR (i.e. induction phase of sensitization) (P 44–48)
—Following PPI assessment (P44), rats were assigned to one of three drug treatment
groups: vehicle (VEH, 1% glacial acetic acid in sterile water), OLZ 1.0 mg/kg, and OLZ 2.0
mg/kg and tested daily for avoidance response for 5 consecutive days. Rats were assigned
such that offspring from the same litter were placed in different groups to minimize litter.
The complete factorial design thus consisted of two prenatal treatments (MIA and saline
offspring) × three drug doses (VEH, OLZ 1.0 mg/kg, and OLZ 2.0 mg/kg), with the saline
offspring treated with vehicle during adolescence serving as the main control comparison
group. The CS-only (no shock, 30 trials/daily session) condition was used to eliminate any
relearning effect caused by the presence of the US. During each drug test, rats were first
injected with OLZ or VEH and placed in the CAR boxes and tested 1 h later.

Author Manuscript

OLZ challenge test (i.e. expression phase of sensitization) (P51)—At the end of
the drug test session (P49) all rats were retrained drug-free for two days, the first under CSonly condition (no shock) and the second under CS-US, to ensure all groups had a
comparable level of avoidance responding before the sensitization assessment. OLZ
sensitization was assessed 1 day later (P51), when all rats were injected with a challenge
dose of OLZ 0.5 mg/kg and tested for avoidance performance 1 h later.

Author Manuscript

BrdU immunohistochemistry for hippocampal cell proliferation and survival—
The BrdU immunohistochemistry technique was modified based on Cameron, 2006. Half of
the animals in each prenatal and drug treatment group received 3 BrdU injections spaced 2 h
apart following the PPI assessment (P43), while the other half received the injections on the
first CAR retraining day (P49). The P43 injection allowed for short term cell survival
assessment as the animals were sacrificed nine days later, while the P49 injection allowed
for cell proliferation assessment as the animals were sacrificed after 48 hours. BrdU is a
synthetic thymidine analogue preferentially incorporated into actively replicating cells. It is
commonly used as a measure of cell proliferation as well as cell survival depending on the
duration between BrdU injection and the time of examination of BrdU immunoreactivity in
tissues (Gratzner, 1982).
The time points chosen in the current study is based on two considerations. First, for cell
proliferation, we chose to inject BrdU 48 hours prior to sacrifice, one day after the last day
of repeated OLZ administration, and animals were immediately sacrificed after the final
OLZ challenge test. This allows for examination of how repeated OLZ treatment affects cell
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proliferation without the contamination of the acute effect of OLZ exposure in the last
challenge, as the time between challenge and sacrifice is too short for complete mitosis.
Secondly, for cell survival, we chose to inject BrdU 9 days prior to sacrifice, one day prior
to the start of repeated OLZ administration. This allows for examination of how repeated
OLZ treatment affects cell survival without the contamination of other environmental factors
post repeated treatment to alter cell survival. The durations were also chosen based on a
parametric study by Dayer et al, 2003. The study concluded that BrdU signals two days post
injection were highly co-expressed with Ki-67, a marker present in cells in all active phases
of the cell cycle, and also frequently used as a marker of cell proliferation (Kee et al, 2002;
Muskhelishvili et al, 2003). This suggests that BrdU+ cells identified two days post BrdU
injection are representative of actively dividing cells (i.e. cell proliferation). The study also
concluded that BrdU signals eight days post injection were not co-expressed with Ki-67,
indicating that these cells were no longer in the mitotic phase and not representative of
newly added daughter cells. This suggests that BrdU+ cells identified at eight days (nine in
the current study) post BrdU injection are representative of cells that survived after leaving
the cell cycle.

Author Manuscript

Following OLZ sensitization challenge test (P51), all rats were deeply anesthetized with
sodium pentobarbital (100.0 mg/kg, ip) and transcardially perfused with 0.02M phosphate
buffered saline (PBS) followed by 4% paraformaldehyde (PFA, pH 7.4) in 0.1M PBS.
Brains were then harvested, post-fixed in 4% PFA overnight and cryoprotected in 30%
sucrose for 72 hours. Serial coronal sections (35μm) of the hippocampus (Bregma −2.0 to
−4.5; Paxinos and Watson, 2007) were cut on a cryostat, and every twelfth section in series
(6 sections per animal) were processed for BrdU labeling. Free floating sections were
incubated in 2M HCl at 37°C for 30 min, followed by two 15 min incubations of 40mM
borate buffer. Sections were then incubated in blocking solution (0.3% Triton X-100 and
10% normal horse serum in 0.02M PBS) for 1 h, followed by 3% H2O2 with 100% methanol
for 30 min, and then in primary antibody at 4°C overnight (mouse anti-BrdU, 1:15,000;
Millipore, Billerica, MA). Secondary antibody (biotinylated horse anti-mouse IgG, 1:500;
Vector Laboratories, Burlingame, CA) incubated sections for 1 h, followed by avidinbiotinylated enzyme complex (Vectastain Elite ABC kit, Vector Laboratories, Burlingame,
CA) for another hour. 3,3′-diaminobenzidine (DAB peroxidase substrate, Vector
Laboratories, Burlingame, CA) was used to reveal BrdU labeling. Normal horse serum
substitution for primary antibody was used as negative control.
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Cell counting was conducted by an experimenter blinded to the conditions. Cells were
viewed with an Olympus CX41RF microscope (Japan) under 200× magnification, and those
with clear delineation of staining in the granule cell layer of the hippocampal DG were
counted. A modified stereological procedure adapted from previous reports (Cameron and
McKay, 2001; Eisch et al, 2000; Gould et al, 1999; Malberg et al, 2000; West et al, 1991)
was used for analysis, which consisted of counting all BrdU-labeled cells bilaterally for each
section, then multiplying the sum of the 6 sections by 12 in order to estimate the total
number of BrdU+ cells per DG.
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All data were expressed as mean ± standard error of mean. One way analysis of variance
(ANOVA) was used to compare pregnant dam weight changes one-day after PolyI:C or
saline treatment. Repeated measures two-way ANOVA (between-subjects factor: prenatal
treatment; within-subjects factor: call type) was conducted on pup USV. Repeated measures
two-way ANOVA (between-subjects factor: prenatal treatment or drug groups; withinsubjects factor: days) was also used for CAR training and drug test sessions. In addition,
percent PPI data for the 3 prepulse intensities (e.g. 73, 76 and 82 dB) were analyzed with
repeated measures two-way ANOVA (between-subjects factor: prenatal treatment; withinsubjects factor: prepulse types). Data from CAR retraining, sensitization assessment, and
cell counting were analyzed by multi-factorial ANOVA (prenatal treatment × drug groups).
Pearson product-moment correlational analysis was conducted between percentage of
avoidance suppression, as assessed by calculating the percent decrease in the number of
avoidances made during either day two of drug administration or challenge day compared to
day one of drug administration, and number of BrdU+ cells. All significant differences were
followed by post hoc LSD tests. For all analyses, p < 0.05 was considered statistically
significant.
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Highlights
1.

Adolescent olanzapine use causes sensitization in immune activated offspring.

2.

Sensitization magnitude correlates negatively with cell survival in controls.

3.

Magnitude correlates positively with cell growth in immune activated offspring.
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Assessment of MIA induced alterations in infancy and adulthood. Percentage of pregnant
dam weight changes one day following saline (SAL) or PolyI:C (MIA) treatment on G15
(a). Maternal separation induced pup ultrasonic vocalizations on P11 (b). Numbers of
ultrasonic vocalizations for each call type (short, long, frequency modulating [mod], total)
made by offspring from the prenatal SAL and MIA treatment groups. Amphetamine-induced
hyperlocomotion on P84 (c). Mean locomotor activities measured as numbers of photobeam
breaks during the 60-min test period after the amphetamine injection made by offspring
from the prenatal SAL and MIA treatment groups. All data are expressed as mean ± SEM.
*p<0.005 and &p=0.054 between prenatal treatment conditions; **p<0.001 between call
types; ##p<0.005 and #p<0.05 relative to the saline group.
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Figure 2.
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Conditioned avoidance response acquisition. Percentages of avoidance responses made by
offspring from the prenatal SAL and MIA treatment groups during the ten days of
conditioned avoidance training (a). Prepulse inhibition (b) and acoustic startle response (c)
assessment post conditioned avoidance response training. All data are expressed as mean ±
SEM. *p<0.05 between prenatal treatment conditions.
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Figure 3.
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Olanzapine sensitization and assessment. Repeated olanzapine administration in conditioned
avoidance response (a,b). Percentages of avoidance responses made by rats from each drug
group (VEH, OLZ 1.0, and 2.0 mg/kg) in the two separate prenatal treatment conditions (a,
saline [SAL] and PolyI:C [MIA]) and with the prenatal conditions combined (b) throughout
the five drug test days. Assessment of olanzapine sensitization in conditioned avoidance
response (c,d). Percentages of avoidance responses made by rats from each drug group
(VEH, OLZ 1.0 and 2.0 mg/kg) in the two separate prenatal treatment conditions (c, SAL
and MIA) and with the prenatal conditions combined (d) on the retraining days and the OLZ
sensitization assessment day. All data are expressed as mean ± SEM. *p<0.001 between
drug treatment conditions.
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Figure 4.
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BrdU analysis of olanzapine associated cell proliferation and survival. Sample micrograph
of BrdU+ cells (dark brown) in the granule cell layer of the hippocampal dentate gyrus (a).
Assessment of cell proliferation (b). Estimated numbers of BrdU+ cells throughout the entire
dentate gyrus for animals in each prenatal and drug treatment condition treated with BrdU
two days prior to sacrifice. Assessment of cell survival (c). Estimated numbers of BrdU+
cells throughout the entire dentate gyrus for animals in each prenatal and drug treatment
condition treated with BrdU nine days prior to sacrifice. All data in b and c are expressed as
mean ± SEM. Correlational analyses of olanzapine sensitization and cell proliferation in the
hippocampal dentate gyrus (d,e). Number of BrdU+ cells two days post BrdU injection was
positively associated with the percent of avoidance suppression induced by olanzapine in
MIA offspring, r=0.527, p=0.030 (e). Correlational analyses of olanzapine sensitization and
cell survival in the hippocampal dentate gyrus (f, g). Number of BrdU+ cells nine days post
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BrdU injection was negatively associated with the percent of avoidance suppression induced
by olanzapine in SAL offspring, r= −0.910, p<0.001 (f).
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